Spotlight Stories
-
From Biggest Pharma To Rare Disease Start-Up
6/1/2023
Martin Mackay’s journey from Pfizer executive to founding and leading a rare disease biotech is a reflection of the industry’s evolution from a small molecule powerhouse to multimodal biotech.
-
Leading Aulos Bioscience’s “Triumvirate” Model
6/1/2023
Aulos Bioscience hopes to leverage its unique business model, engineered by a VC firm and an Israeli biotech, to develop better treatments for solid tumors.
-
A Quick Transition To Late-Stage Clinical Trials
6/1/2023
“Moving into Phase 3 not only expands the resources you need internally, but some things require a much larger amount of capital, and often a public listing so you can raise larger amounts of money,” says Eric Dobmeier, president and CEO, Chinook Therapeutics.
-
Fortress Biotech’s Network Flex Business Model
5/1/2023
Fortress Biotech CEO Lindsay Rosenwald talks up Fortress Biotech’s business model, which leverages partner companies to develop promising but underexposed drug candidates.
-
The Skin Is The Game: New Ways To Play In Dermatology
5/1/2023
As the established indications in dermatology become saturated with competing products, a variety of companies, from start-ups to oncology players, are finding opportunities in underserved indications and reformulated drugs.
-
Building It All In-House
5/1/2023
Kriya’s firm commitment to build or bring all key functions in house may be unusual for such a young enterprise, but it has been consistent from the beginning.
-
Hitting The Ground Running In Oncology
4/3/2023
David Lee, CEO at Servier Pharmaceuticals, talks about how he set up the French company’s U.S. division, and his goal of reaching $2 billion in annual oncology product revenue.
-
Vor Bio’s Transition Into Clinical Trials
4/3/2023
Vor Bio’s story, for all of its uniqueness, can teach important lessons in many different quarters, involving everything from mundane tactics to dramatic strategies.
-
U.S. Patent Expired? Why Not Grow Revenue Globally, Says Amarin
4/3/2023
Amarin is deploying a global strategy to expand patient access to Vascepa, hoping to make up for lost revenues in the U.S.
-
The Neo CEO
3/1/2023
Lex Rovner founded her company with support from academic scientists and has headed it since it opened for business in 2018. At that time, she had no prior experience as a company founder or as a CEO.